RUA Stock Overview
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
RUA Life Sciences plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.54 |
| 52 Week High | UK£0.67 |
| 52 Week Low | UK£0.31 |
| Beta | 1.27 |
| 1 Month Change | 13.68% |
| 3 Month Change | 56.52% |
| 1 Year Change | 0.93% |
| 3 Year Change | -37.57% |
| 5 Year Change | 14.89% |
| Change since IPO | -96.10% |
Recent News & Updates
Shareholder Returns
| RUA | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -10.7% | 3.9% | 0.8% |
| 1Y | 0.9% | -2.9% | -4.6% |
Return vs Industry: RUA exceeded the UK Medical Equipment industry which returned -4.8% over the past year.
Return vs Market: RUA exceeded the UK Market which returned -3.7% over the past year.
Price Volatility
| RUA volatility | |
|---|---|
| RUA Average Weekly Movement | 14.5% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: RUA is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: RUA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 38 | n/a | https://rualifesciences.com |
RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves.
RUA Life Sciences plc Fundamentals Summary
| RUA fundamental statistics | |
|---|---|
| Market Cap | UK£11.98m |
| Earnings (TTM) | -UK£1.90m |
| Revenue (TTM) | UK£2.02m |
5.9x
P/S Ratio-6.3x
P/E RatioIs RUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RUA income statement (TTM) | |
|---|---|
| Revenue | UK£2.02m |
| Cost of Revenue | UK£316.00k |
| Gross Profit | UK£1.71m |
| Other Expenses | UK£3.60m |
| Earnings | -UK£1.90m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | 84.36% |
| Net Profit Margin | -93.96% |
| Debt/Equity Ratio | 8.2% |
How did RUA perform over the long term?
See historical performance and comparison